Stockscreener 앱 받기
0.5351
2.90%
0.0151
시간 외 거래:
.51
-0.0251
-4.69%
전일 마감가:
$0.52
열려 있는:
$0.5174
하루 거래량:
105.27K
Relative Volume:
0.02
시가총액:
$4.96M
수익:
$5.07M
순이익/손실:
$-10.18M
주가수익비율:
-0.1269
EPS:
-4.2178
순현금흐름:
$-7.93M
1주 성능:
+8.10%
1개월 성능:
+31.47%
6개월 성능:
-78.34%
1년 성능:
-76.11%
1일 변동 폭
$0.5001
$0.539
1주일 범위
$0.4546
$0.60
52주 변동 폭
$0.3144
$4.85
Ensysce Biosciences Inc Stock (ENSC) Company Profile
명칭
Ensysce Biosciences Inc
전화
(858) 263-4196
주소
7946 IVANHOE AVENUE, LA JOLLA
Compare ENSC vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
0.5351 | 4.82M | 5.07M | -10.18M | -7.93M | -4.2178 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ensysce Biosciences Inc 주식(ENSC)의 최신 뉴스
Price Action: Will Ensysce Biosciences Inc benefit from geopolitical trendsTrade Volume Summary & Weekly High Potential Alerts - baoquankhu1.vn
Bull Run: Is Ensysce Biosciences Inc subject to activist investor interest2026 Dividend Review & Free Reliable Trade Execution Plans - baoquankhu1.vn
ENSC Should I Buy - Intellectia AI
Ensysce Biosciences (NASDAQ: ENSC) registers 20.3M resale shares - Stock Titan
Ensysce Biosciences Secures $2 Million Second Tranche Financing to Advance Abuse-Resistant Pain Therapies - Minichart
Ensysce Biosciences Secures $2 Million Private Financing - TipRanks
Ensysce Biosciences (NASDAQ: ENSC) closes $2M preferred and warrant deal - Stock Titan
Ensysce Raises $2 Million in Private Placement of Series B Preferred and Warrants - TradingView — Track All Markets
Ensysce Biosciences closes $2M convertible preferred financing By Investing.com - Investing.com South Africa
Ensysce Biosciences Secures Second Financing to Advance Pain Programs - National Today
Ensysce Biosciences closes $2M convertible preferred financing - Investing.com
Pain drug developer pulls another $2M for overdose-resistant treatments - Stock Titan
Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs - The Globe and Mail
Aug Swings: Does Ensysce Biosciences Inc meet Warren Buffetts criteria2026 Patterns & Reliable Intraday Trade Alerts - baoquankhu1.vn
Stop Loss: Whats the RSI of PETWW stock2026 Sector Review & Real-Time Volume Triggers - baoquankhu1.vn
Ensysce Biosciences, Inc. Announces Director Resignation in April 2026 Form 8-K Filing - Minichart
Ensysce Biosciences director Curtis Rosebraugh resigns from board By Investing.com - Investing.com India
Ensysce Biosciences director Curtis Rosebraugh resigns from board - Investing.com
Ensysce Biosciences Announces Board Member Curtis Rosebraugh Resignation - TipRanks
Board member Curtis Rosebraugh exits Ensysce Biosciences (NASDAQ: ENSC) - Stock Titan
ENSC SEC FilingsEnsysce Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ENSC Stock Price, Quote & Chart | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
Ensysce Biosciences, Inc. — Business Overview, Risk Factors, Regulatory Approvals, and Intellectual Property Challenges 64 - Minichart
8-K: Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results - Moomoo
Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results - bitget.com
Smart Money: Will Ensysce Biosciences Inc benefit from geopolitical trendsWeekly Market Summary & Growth Oriented Trading Recommendations - baoquankhu1.vn
Ensysce Biosciences (NASDAQ: ENSC) outlines abuse-resistant opioid pipeline - Stock Titan
ENSC: Net loss widened to $10.2 million in 2025; ongoing operations depend on new capital raises - TradingView — Track All Markets
Ensysce Biosciences Reports Q4 and Full Year 2025 Results - National Today
Ensysce (NASDAQ: ENSC) advances PF614 programs as 2025 net loss hits $10.2M - Stock Titan
Ensysce Biosciences Q4 net loss narrows to $2.8 mln - TradingView
Ensysce pushes abuse-deterrent opioid into late-stage testing - Stock Titan
Ensysce Biosciences (NASDAQ: ENSC) director quits after opposing retention deals - stocktitan.net
Revenue Check: Does Ensysce Biosciences Inc meet Warren Buffetts criteria2026 Highlights & Low Risk High Reward Ideas - baoquankhu1.vn
Weekly Trades: Is Ensysce Biosciences Inc a turnaround story2026 Snapshot & Fast Exit and Entry Trade Guides - baoquankhu1.vn
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Ensysce Biosciences Files Certificate of Correction for Series B Preferred Stock with Delaware Secretary of State - Minichart
Ensysce Biosciences files correction to Series B preferred stock designation By Investing.com - Investing.com South Africa
Ensysce Biosciences Corrects Series B Preferred Stock Designation - TipRanks
Ensysce Biosciences files correction to Series B preferred stock designation - Investing.com
Ensysce Biosciences (ENSC) files correction to Series B preferred stock - Stock Titan
If You Invested $1,000 in Ensysce Biosciences Inc (ENSC) - Stock Titan
Earnings Recap: Is Travere Therapeutics Inc stock heavily shorted2026 Technical Patterns & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Risk Analysis: Is Ensysce Biosciences Inc being accumulated by smart money2026 Setups & Daily Profit Focused Screening - baoquankhu1.vn
Ensysce Biosciences Inc expected to post a loss of $1.26 a shareEarnings Preview - TradingView
ENSC Earnings History & Surprises | EPS & Revenue Results | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
Market Fear: Will Ensysce Biosciences Inc benefit from geopolitical trendsJuly 2025 Setups & Smart Swing Trading Alerts - baoquankhu1.vn
Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Pl - PharmiWeb.com
CEO takes live questions on Ensysce PF614 pain-drug plans - Stock Titan
Ensysce publishes phase 1 data on overdose-limiting opioid tech By Investing.com - Investing.com Australia
Ensysce Biosciences Inc (ENSC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):